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Abstract
Introduction: The receptor activator nuclear factor-kappaB ligand (RANKL) diffuses from articular cartilage to
subchondral bone. However, the role of chondrocyte-synthesized RANKL in rheumatoid arthritis-associated juxta-
articular bone loss has not yet been explored. This study aimed to determine whether RANKL produced by
chondrocytes induces osteoclastogenesis and juxta-articular bone loss associated with chronic arthritis.
Methods: Chronic antigen-induced arthritis (AIA) was induced in New Zealand (NZ) rabbits. Osteoarthritis (OA) and
control groups were simultaneously studied. Dual X-ray absorptiometry of subchondral knee bone was performed
before sacrifice. Histological analysis and protein expression of RANKL and osteoprotegerin (OPG) were evaluated in
joint tissues. Co-cultures of human OA articular chondrocytes with peripheral blood mononuclear cells (PBMCs)
from healthy donors were stimulated with macrophage-colony stimulating factor (M-CSF) and prostaglandin E2
(PGE2), then further stained with tartrate-resistant acid phosphatase.
Results: Subchondral bone loss was confirmed in AIA rabbits when compared with controls. The expression of
RANKL, OPG and RANKL/OPG ratio in cartilage were increased in AIA compared to control animals, although this
pattern was not seen in synovium. Furthermore, RANKL expression and RANKL/OPG ratio were inversely related to
subchondral bone mineral density. RANKL expression was observed throughout all cartilage zones of rabbits and
was specially increased in the calcified cartilage of AIA animals. Co-cultures demonstrated that PGE2-stimulated
human chondrocytes, which produce RANKL, also induce osteoclasts differentiation from PBMCs.
Conclusions: Chondrocyte-synthesized RANKL may contribute to the development of juxta-articular osteoporosis
associated with chronic arthritis, by enhancing osteoclastogenesis. These results point out a new mechanism of
bone loss in patients with rheumatoid arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic disease character-
ized by both synovial and systemic inflammation, with
primary joint involvement. The intense inflammatory
process seen in the disease is the most important risk
factor for progressive destruction of extracellular
matrices of articular cartilage and bone in joints affected
by RA [1-3]. Three principal forms of bone loss have
been described in patients with RA: focal bone erosions,
juxta-articular bone loss, and systemic bone loss [4]. Of
these, juxta-articular bone loss represents a common
and early feature of RA that affects the trabecular bone
adjacent to the inflamed joint [5]. In spite of this, the
pathogenesis of juxta-articular bone loss in RA has not
yet been fully elucidated, mainly because of the difficul-
ties in obtaining appropriate human samples for study.
Nevertheless, the loss of periarticular bone in RA has
been associated with dysregulation of bone remodeling,
which is redirected towards the predominance of resorp-
tion activity over formation [6].
Different hormones, cytokines and chemokines pro-
duced by the inflamed synovial membrane have been
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reported to be involved in juxta-articular osteoporosis in
RA [4]. Also, the pannus directly infiltrates osseous tis-
sue contributing to periarticular bone loss [7]. Certainly,
juxta-articular bone loss is related to the intensity of
inflammatory response in the affected joint [2-7]. This
fact is observed not only in RA, but also in other arthri-
tides associated with a high degree of inflammation
[8,9]. Macrophages differentiate into bone-resorbing
osteoclasts in zones of contact between the inflamed
synovium and subchondral bone in RA in the presence
of a crucial factor, the receptor activator of nuclear fac-
tor-B ligand (RANKL) [10,11].
RANKL is markedly involved in osteoclastogenesis,
osteoclast migration, adherence to bone, and apoptosis
regulation due to its binding to the receptor activator of
nuclear factor-B (RANK) [12], which is expressed on
osteoclast precursors and mature osteoclasts. A study by
Pettit, et al showed that tumor necrosis factor-related
activation-induced cytokine (TRANCE) knockout mice
were deficient in osteoclasts and protected from bone
loss in a serum transfer model of arthritis, demonstrat-
ing in vivo the importance of RANKL and osteoclasto-
genesis in bone loss associated with RA [13]. The pro-
osteoclastogenic actions of RANKL are physiologically
regulated by osteoprotegerin (OPG), a soluble non-sig-
nalling receptor for RANKL [14]. Indeed, OPG competi-
tively inhibits RANKL binding to its receptor RANK. In
healthy joints, RANKL expression has been described in
bone lining cells of osteoblast lineage, synovial T cells,
and chondrocytes [9,15-19], whereas in inflamed
arthritic joints, it is detected in synovial fibroblasts, T
and B cells, osteoclasts, and chondrocytes [6,20-23].
Proinflammatory cytokines such as tumor necrosis
alpha (TNF-a), interleukin (IL)-1b, IL-6, IL-7, and IL-
17, as well as macrophage-colony stimulating factor (M-
CSF), parathyroid hormone (PTH), 1,25-dihydroxychole-
calciferol [1,25(OH)2D3], and prostaglandin E2 (PGE2)
increase RANKL synthesis [3,4,24,25]. More recently,
transcriptional repressors that suppress RANKL-induced
gene expression and osteoclast differentiation have been
described, including IL-4/IL-13 and granulocyte-macro-
phage colony stimulating factor (GM-CSF), IL-10, IL-27,
interferon-g, TNF apoptosis related inducing ligand
(TRAIL), IL-12, IL-18, IL-6, and toll-like receptors [26].
Thus, the extent of bone destruction in inflammatory
arthritis is determined by the balance between osteoclas-
togenic and anti-osteoclastogenic factors, with the rele-
vant biological mediation of RANKL.
In addition to membrane-bound RANKL in osteo-
blasts [27], RANKL secreted by synovial cells actively
promotes bone destruction in chronic inflammatory
arthritis [21,23]. Hence, high local RANKL concentra-
tions may lead to increased osteoclastogenesis at the
bone-pannus interface. However, scarce attention has
been given to the potential role of the RANKL
expressed by chondrocytes in the pathogenesis of RA-
related juxta-articular bone loss, although it has been
reported to diffuse from the cartilage to subchondral
bone in human osteoarthritis (OA) [28]. Accordingly,
we hypothesized that RANKL produced in articular car-
tilage might contribute to juxta-articular bone loss in
chronic arthritis.
Animal models of RA offer a valuable opportunity to
enhance our understanding of the pathogenic mechan-
isms underlying juxta-articular bone loss in the disease.
To optimize this potential, we characterized an experi-
mental model of chronic arthritis that represents a more
intense and destructive version of the well-established
antigen-induced arthritis (AIA) [29-31]. This inflamma-
tory arthritis is accompanied by severe juxta-articular
bone loss, as estimated by x-ray and bone mineral den-
sity (BMD). Thus, our experimental model is suitable to
study the role of RANKL, OPG, and RANKL/OPG ratio
in the pathogenesis of juxta-articular bone loss in
chronic arthritis.
Therefore, we carried out an in vivo study to explore
the potential effect of cartilage-synthesized RANKL on
juxta-articular bone loss associated with RA.
Materials and methods
Animals
Studies were carried out in 18 adult male New Zealand
rabbits with a body weight of 3.0 to 3.5 kg (Granja San
Bernardo, Navarra, Spain). Animal handling and experi-
mentation were performed in accordance with Spanish
regulations and the Guidelines for the Care and Use of
Laboratory Animals drawn up by the National Institutes
of Health (Bethesda, MD, USA). The experimental pro-
tocol was approved by the Institutional Ethics Commit-
tee. All rabbits were allowed to adapt to the facilities for
one week and were then randomly separated into three
groups: 1) eight healthy rabbits (healthy group), 2) three
rabbits with OA (OA group), and 3) seven rabbits with
chronic antigen-induced arthritis (AIA group).
Experimental model of chronic arthritis
AIA was induced in rabbits as previously described in
detail [31]. Briefly, animals were given two intradermal
injections of 4 mg ovalbumin (OVA; Sigma-Aldrich, St.
Louis, MO, USA) in Freund’s complete adjuvant (Difco,
Detroit, MI, USA). Beginning five days after the second
injection, 1 ml of OVA (5 mg/ml in 0.9% NaCl) was
injected into the knee joints on a weekly basis over the
following four weeks. The animals were euthanized at
the end of this period to evaluate chronic damage and
not acute damage (Figure 1A). Samples of the synovial
membrane, articular cartilage, and subchondral bone in
each knee were collected for further studies.
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Experimental model of OA
In order to establish a control for rheumatic disease that
occurs with a lower inflammatory response and a lower
subchondral bone loss than chronic arthritis, surgical
OA was induced in the knees of rabbits following a pre-
viously described protocol [32]. Consequently, partial
medial meniscectomy and anterior cruciate ligament
(ACL) sectioning were performed. The rabbits were
euthanized at the end of the eighth week (Figure 1A),
and knee joint tissues were obtained for further studies.
Radiographic analysis and BMD measurements
To determine the presence of juxta-articular osteoporo-
sis in rabbit knees, radiographic analysis and BMD mea-
surements were taken just before the mice were
euthanized. In the healthy group, these assessments
were carried out at week 9 of the study.
Digital x-ray images of the knee were obtained from
rabbits placed in the supine decubitus position. All
radiographs were performed by the same operator using
the Philips Diagnost 93 system (Philips Medical Systems,
Eindhoven, The Netherlands), at 60 kV, 200 mA, 100
ms (Konica Minolta Medical film 27.9 × 35.6 cm; Case-
tte Regius RC-110, Konica Minolta, USA). Radiographs
were obtained using a vertical x-ray beam centered over
the femorotibial joints and collimated from the mid-
femur to the mid-tibia [33].
To determine BMD, all rabbits underwent dual-energy
x-ray absorptiometry (DXA) according to previously
reported work [34]. DXA was carried out using a Holo-
gic QDR-1000/WTM pencil-beam densitometer with a
1 mm diameter collimator on the x-ray output (Hologic
Inc., Waltham, MA, USA). Briefly, BMD was measured
at the left knee joint with animals placed in the supine
decubitus position. Four subarticular regions, each 0.06
cm2, corresponding to the medial and lateral femoral
condyles and tibial plateaus, were selected. These
regions were located, respectively, 1 mm above and
below the joint line at the areas of maximum contact
between the femoral condyles and tibial plateaus. The
mean BMD values were considered representative of
subchondral bone.
Western-blot analysis
Tissues from synovial membranes, cartilage, and tibial
subchondral bone were homogenized in liquid nitrogen,
and total protein was extracted from the resulting pow-
der by a protein extraction buffer containing 15 mM
Figure 1 Schematic representation of experimental models and evaluation of juxta-articular bone loss. (A) Antigen-induced arthritis (AIA)
was induced in seven rabbits by immunization and following weekly intra-articular knee injections of ovalbumin (OVA). Surgical osteoarthritis
(OA) was induced in the knees of three rabbits by partial medial meniscectomy (PMM) and transection of the anterior cruciate ligament (ACLT).
(B) Representative antero-posterior radiography of the knees in each group of rabbits. (C) Densitometric analysis of subchondral bone mineral
density (BMD, g/cm2) in each group of rabbits. The results are expressed as mean ± standard deviation (SD) for healthy rabbits (H), and rabbits
with osteoarthritis (OA) and chronic antigen-induced arthritis (AIA).
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HEPES, 10% glycerol, 0.5% NP-40, 250 mM NaCl, 1
mM EDTA, 1:1000 PMSF, and a protease inhibitor
cocktail (Sigma-Aldrich, St Louis, MO, USA). Protein
determination was carried out as described previously
[35], and subsequently 20 μg of total protein from each
tissue was resolved on 15% acrylamide-SDS gels. After
transfer to polyvinylidene difluoride (PVDF) membranes
(Millipore, Molsheim, France) in 48 mM Tris, 39 mM
glycine, and 20% methanol at 20 V for 1 h at room tem-
perature, membranes were blocked in 5% skimmed milk
in PBS-Tween 20 for 1 h at room temperature and incu-
bated overnight at 4°C with anti-RANKL antibodies
(Peprotech, Neuilly-Sur-Seine, France) and OPG (R&D
systems, Minneapolis, MN, USA) at 1/1000 dilution
each. Antibody binding was detected by enhanced che-
moluminescence using peroxidase-labelled secondary
antibodies, and the results were expressed as arbitrary
densitometric units (AU). Loading control was per-
formed on 15% acrylamide-SDS gels by employing
EZBlue’ Gel Staining Reagent (Sigma-Aldrich, St Louis,
MO, USA).
In addition, the total amount of RANKL resulting
from the sum of cartilage, synovium, and subchondral
bone expressions was considered as the RANKL global
expression in joint tissues. Thus, RANKL global expres-
sion was estimated as 100% and the contribution of
each joint tissue was estimated in partial percentages.
Cartilage and subchondral bone histology
After sacrifice, femur sections were fixed in 4% parafor-
maldehyde and further decalcified for 4 weeks in a solu-
tion made up of 10% formic acid plus 5%
paraformaldehyde. The decalcified knee joints were
cleaved in a sagittal plane along the central portion of
the articular surface of each medial femoral condyle cor-
responding to the weight-bearing area, and were then
embedded in paraffin block. Sections of 4 μm were
stained with safranin-O Fast Green to assess pathologi-
cal changes in cartilage. These samples were evaluated
using a modified version of Mankin’s grading score sys-
tem. The Mankin score has been used by other authors
to analyze cartilage damage in arthritic samples [36].
Thus, partial scores evaluating structure abnormalities,
cellularity, and matrix staining (tidemark integrity was
omitted) were calculated and further combined to give a
maximum total score of 21 for each histological section.
Each cartilage sample was evaluated twice by two
experienced observers, and the mean of two reading
scores was used in all statistical analyses. Samples were
presented to observers in random order. The observers
were blinded with respect to each other’s reading, and
rabbit group. Assessment of cartilage histology was per-
formed at the weight-bearing surface of the medial
femoral condyle because it shows the earliest and most
severe histological abnormalities [37].
Other sections were stained with Alcian blue-PAS and
photographed at 4× magnification to evaluate subchon-
dral bone plate thickness. The subchondral bone plate
thickness was assessed in five different regions of the
femoral condyle, including the pannus-bone interface
(regions I and V), subchondral bone under the weight-
bearing femoral surface (regions III and IV; Figure 2A),
and subchondral bone close to the anterior synovial-
bone interface (region II; Figure 2B). A straight line link-
ing both pannus-bone interfaces was divided into five
equal fragments to delineate the regions of interest.
Then, two tangential lines were drawn: the first at the
intersection between articular cartilage and the initial
cortical layer of the subchondral bone, and the second
at the point where the subchondral bone ends. The dis-
tance between these two lines was taken to define the
subchondral bone plate thickness in the five regions
(Figure 2D).
Immunohistochemical localization of RANKL and OPG
Paraffin-embedded femur sections of 4 μm were pre-
pared to detect the distribution pattern of cells expres-
sing RANKL and OPG. The sections were incubated
with antibodies against OPG (R&D Systems, Minneapo-
lis, MN, USA) and RANKL (Santa Cruz Biotech, Heidel-
berg, Germany). The antibodies were detected with a
biotinylated donkey anti-goat immunoglobulin G (IgG)
and visualized with horseradish peroxidase/ABComplex
using 3,3’-diaminobenzidine tetrahydrochloride as the
chromogen (Dako, Camarillo, CA, USA). The tissues
were counterstained and mounted in DPX (VWR Inter-
national Ltd, Poole, England). The negative controls
involved incubation with an IgG isotype.
Cell culture
Following procedures approved by the local Ethical
Committee, chondrocytes were isolated from the joint
cartilage of OA patients who had undergone knee repla-
cement surgery in the Orthopedic Surgery Department
of Fundación Jiménez Díaz. Written informed consent
was obtained from all patients. The chondrocytes were
obtained after sequential digestion with trypsine (Lonza
Group Ltd, Basel, Switzerland) for 15 minutes and col-
lagenase type IV (Sigma-Aldrich, St Louis, MO, USA; 1
g/l) for 6 h, both at 37°C. The chondrocytes were grown
to confluence in DMEM (Lonza Group Ltd, Basel, Swit-
zerland) supplemented with 10% fetal calf serum, 60 U/
ml penicillin, 60 μg/ml streptomycin, and 2 mmol/l glu-
tamine at 37°C in the presence of 5% CO2. Simulta-
neously, peripheral blood mononuclear cells (PBMCs)
were isolated from healthy donors by Ficoll gradient cell
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separation (Histopaque - 1077; Sigma-Aldrich, St. Louis,
MO, USA). PBMCs were cultured for 24 h at a density
of 2 million cells/well in 6 well-plates in a-MEM sup-
plemented with 10% fetal calf serum, 60 U/ml penicillin,
60 μg/ml streptomycin, 2 mmol/l glutamine, and 40 ng/
ml of M-CSF (Sigma-Aldrich, St. Louis, MO, USA) at
37°C in the presence of 5% CO2.
Subsequently, confluent chondrocytes were re-sus-
pended in a-MEM supplemented with 10% fetal calf
serum and co-cultured with PBMCs at a density of
Figure 2 Histological evaluation of juxta-articular bone thickness. (A) Representative sections of subchondral bone stained with Alcian blue-
PAS from weight-bearing regions in each group (original magnification ×100). (B) Representative sections of pannus-associated regions in each
group (original magnification ×100). (C) Densitometric analysis of subchondral bone plate thickness in each group of rabbits. The results are
expressed as mean ± standard deviation (SD). (D) Schematic view of subchondral bone measurements performed in five regions of interest of
the femoral condyle in healthy rabbits (H), and rabbits with osteoarthritis (OA) and chronic antigen-induced arthritis (AIA).
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90,000 cells/well for 21 days in the presence of 40 ng/ml
M-CSF (Sigma-Aldrich, St. Louis, MO, USA) and where
indicated, 10-6 M PGE2 (Cayman Chemical, Ann Arbor,
MI, USA). Two osteoclastogenic inhibitors, anti-RANKL
antibody (Peprotech, Neuilly-Sur-Seine, France) and
OPG recombinant protein (Peprotech, Neuilly-Sur-
Seine, France) were used to block osteoclast formation
in the presence of 10-6 M PGE2 in co-cultures. Both the
medium and differentiation factors were changed every
48 h. After 21 days of differentiation, osteoclast differen-
tiation was evaluated by staining for tartrate-resistant
acid phosphatase (TRAP) using a commercial kit
(Sigma-Aldrich, St. Louis, MO, USA). Osteoclasts were
identified by the presence of ≥ 3 nuclei and purple
color.
Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 17.0 software for Windows (SPSS, Chicago, IL,
USA), and results were expressed as the mean ± stan-
dard deviation (SD). The data from multiple groups
were compared using a Kruskal-Wallis nonparametric
test, and a pairwise comparison using the Mann-Whit-
ney test was applied when overall differences were iden-
tified. Spearman correlation coefficients were calculated.
P values less than 0.05 were considered significant.
Results
Juxta-articular bone loss
Radiographic analysis showed that rabbits with AIA had
juxta-articular bone loss and symmetrical joint space
narrowing in the affected knees. However, knees of OA
rabbits had medial joint space narrowing (Figure 1B).
The low densities observed on radiographs were con-
firmed by analyzing subchondral BMD in the knee
bones (Figure 1C). In fact, rabbits with AIA had signifi-
cantly lower BMD than healthy ones (0.27 ± 0.04 vs.
0.55 ± 0.05 g/cm2, P = 0.029). Furthermore, rabbits with
OA also had a stronger tendency for lower BMD than
healthy ones, although the difference was not statisti-
cally significant (0.43 ± 0.06 vs. 0.55 ± 0.05 g/cm2, P =
0.057). We also observed that BMD was lower in rabbits
with AIA than in those with OA, though with limited
statistical significance.
Juxta-articular bone loss observed in AIA rabbits was
confirmed in histological studies. Indeed, thinner and
discontinuous bone trabeculae are seen in AIA rabbits
when compared with healthy ones (Figure 2A). To test
if that bone loss was higher in the zones of bone
invaded by pannus, the subchondral bone plate thick-
ness was evaluated in weight-bearing regions and in
bone-pannus interfaces. Our results showed a greater
thickness in weight-bearing regions than in bone-pannus
interfaces in the healthy group, whereas, in the AIA
group, subchondral bone plate thickness loss was homo-
geneous along the condylar surface (Figure 2C). In addi-
tion, while all AIA rabbits had significant pannus
associated with high osteoclastogenic activity, none of
OA animals presented with pannus or bone erosions.
Furthermore, pannus and bone erosions were only seen
in the synovial membrane-cartilage interface of AIA ani-
mals, but not throughout the remainder of the osteo-
chondral junction, as shown in Figure 2A and 2B.
Histological cartilage damage
Cartilage damage in the knees of our experimental mod-
els was evaluated using a modified histopathological
Mankin grading score [34]. This assessment was per-
formed by two blinded observers, and a high correlation
between both evaluations was obtained (r = 0.95). Carti-
lage samples from AIA and OA rabbits showed total
Mankin scores that were significantly higher than those
from healthy animals (AIA, 12.21 ± 3.15 vs. healthy 1.56
± 2.49, P < 0.001; OA, 8.33 ± 2.36 vs. healthy 1.56 ±
2.49, P = 0.036), as seen in Figure 3. Furthermore, carti-
lage damage was inversely related to subchondral BMD
in all rabbits (r = -0.829, P = 0.021; see Figure S1 in
Additional file 1).
RANKL and OPG protein expression in healthy and
pathological joint tissues
Our western blot results confirmed that both RANKL
and OPG are expressed in healthy cartilage (Figure 4A,
B). RANKL and OPG expression in AIA and OA carti-
lage was also analyzed. The expression of both RANKL
and OPG was higher in cartilage from AIA rabbits than
in cartilage from OA and healthy rabbits (RANKL in
AIA, 876.80 ± 149.52 vs. OA 204.92 ± 52.47, P = 0.017;
vs. healthy 64.15 ± 22.26, P < 0.001 (Figure 4A); OPG in
AIA 153.79 ± 54.63 vs. OA 53.17 ± 4.61, P = 0.017 vs.
healthy 35.63 ± 18.22 AU, P = 0.0001 (Figure 4B).
Moreover, the RANKL/OPG ratio showed an increase in
AIA cartilage when compared to healthy cartilage (6.20
± 2.13 vs. 3.85 ± 0.90, P = 0.009; Figure 4C). An
increased ratio, however, was not found in synovium
(5.21 ± 1.02 vs. 5.14 ± 2.90, P = 0.613; Figure 4C) or
subchondral bone (6.56 ± 1.59 vs. 5.88 ± 4.18, P =
0.397) of AIA rabbits when compared with healthy ones.
In addition, the RANKL/OPG ratio in articular cartilage
was not different from that in synovium in the AIA
group (6.21 ± 2.14 vs. 5.21 ± 1.02, P = 0.902). RANKL
expression and the RANKL/OPG ratio in articular carti-
lage were inversely related to subchondral BMD
(RANKL: r = -0.891, P < 0.001; RANKL/OPG: r =
-0.736, P = 0.01; see Figures S2 and S3 in Additional
file 1).
We also analyzed the relative contribution of each tis-
sue to the articular global RANKL production, and we
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observed that 30% of the total RANKL expressed in an
arthritic knee is produced by the inflamed cartilage, a
tissue with a poor cellular content compared to syno-
vium or subchondral bone (data not shown).
Localization of RANKL and OPG in articular cartilage
Immunohistochemical detection confirmed western blot
results, which showed a higher expression of RANKL
(Figures 5C, D, H and Additional file 2, Figure 1) and
OPG (Figure 5G), throughout the articular cartilage in
AIA rabbits. In healthy cartilage, the RANKL expression
was intracellular and was higher in both superficial and
middle zones than in deep cartilage. In the calcified car-
tilage of these healthy rabbits, a mild expression of
RANKL was again appreciable, and most RANKL+
chondrocytes were located around mesenchymal struc-
tures (Figure 5A). The same RANKL distribution pat-
tern, though with a higher intensity, was gradually
observed in the articular cartilage from OA (Figure 5B)
and AIA rabbits (Figures 5C, D, H; see Figure S1 in
Additional file 2). In the AIA rabbits, we observed that
higher cartilage damage corresponded with a higher
RANKL expression. RANKL expression was predomi-
nantly intra-cellular. However, a clear extracellular
expression of RANKL was also detected in AIA rabbits
(Figure 5D), especially near the vessel in the calcified
cartilage (Figure 5H). Regarding OPG expression in
healthy samples, it was only observed within chondro-
cytes from the deep zone (Figure 5E). The localization
was almost the same for OA (Figure 5F) and AIA rab-
bits (Figure 5G), although we observed an increase in
the intensity of the staining.
RANKL expressed by chondrocytes has osteoclastogenic
activity
Previous studies by our group have demonstrated that
PGE2 induces RANKL expression by chondrocytes in
vitro [28]. Accordingly, and in light of the increased
activity of PGE2 in RA, we stimulated chondrocytes with
PGE2 to replicate in vitro micro-environmental
Figure 3 Histological evaluation of cartilage damage. Representative sections from healthy (A), osteoarthritic (B) and chronic arthritic rabbits
(C) stained with safranin-O Fast Green (original magnification ×100). (D) Bar graph showing the results of modified Mankin score evaluation
carried out at the weight-bearing area of the medial femoral condyles. The results are expressed as mean ± standard deviation (SD) for healthy
rabbits (H), and rabbits with osteoarthritis (OA) and chronic antigen-induced arthritis (AIA).
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conditions occurring in the RA joint. Six experimental
co-culture conditions were developed: 1) co-culture of
PBMCs with chondrocytes in the presence of M-CSF; 2)
co-culture of PBMCs with chondrocytes in the presence
of M-CSF and PGE2; 3) co-culture of PBMCs with
chondrocytes in the presence of M-CSF, PGE2 and anti-
RANKL antibody; 4) co-culture of PBMCs with chon-
drocytes in the presence of M-CSF, PGE2 and OPG
recombinant protein; 5) culture of PBMCs in the pre-
sence of M-CSF and PGE2, and 6) culture of PBMCs in
the presence of M-CSF and RANKL. Our results
demonstrated that basal RANKL production by chon-
drocytes was not enough to induce osteoclastogenesis
from monocytes in vitro (Figure 6A). However, RANKL
produced by PGE2-stimulated chondrocytes induced dif-
ferentiation of monocytes into osteoclasts (Figure 6B
and 6C). In addition, we have observed that both
RANKL inhibitors blocked osteoclastogenesis as no
TRAP+ cells were seen in these two culture conditions
(data not shown).
Discussion
In this study, we have shown that the expression of
both RANKL and OPG were higher in the articular
cartilage of rabbits with AIA than in healthy cartilage.
The localization of RANKL in knee cartilage was also
Figure 4 Receptor activator nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) expression in cartilage, subchondral
bone and synovium. Densitometric analysis of the expression of RANKL (A), OPG (B) and the RANKL/OPG ratio (C) in cartilage, subchondral
bone and synovium. (D) Representative western blot images for RANKL and OPG detection in cartilage, subchondral bone and synovium. EZ
Blue-stained gels used as protein loading controls are also shown for healthy rabbits (H), and rabbits with osteoarthritis (OA) and chronic
antigen-induced arthritis (AIA).
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different between AIA and healthy cartilage. While
both intracellular and clear extracellular RANKL sig-
nals were observed in rabbits with AIA, especially
around the mesenchymal structures in the calcified
cartilage, healthy rabbits showed mild intracellular and
no extracellular RANKL signals in this area. In
addition, the resorptive signal measured by the
RANKL/OPG ratio was increased in the articular car-
tilage of AIA rabbits, and this increase was simulta-
neous to a significant bone loss in the subchondral
plate that was homogeneous along the femoral con-
dyle surface.
Figure 5 Receptor activator nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) distribution patterns in cartilage. RANKL
staining is shown in (A) healthy control cartilage, (B) osteoarthritic cartilage with insets displaying RANKL at the osteochondral junction
(magnifications ×200 and ×400, respectively), and (C) chronic arthritic cartilage (original magnification ×200). Detail of extracellular expression of
RANKL (D), and its location near the blood vessel (H). Insets show RANKL expression at the osteochondral junction (original magnifications ×200
and ×400, respectively). OPG staining is shown in healthy control cartilage (E), osteoarthritic cartilage (F) and arthritic cartilage (G) (original
magnification × 200).
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Systemic bone loss in RA is a multifactorial and com-
plex alteration, in which chronic inflammation plays an
important role. Within the joint, the focal bone erosions
and juxta-articular bone loss are observed at different
localities. Focal bone erosions are mainly observed in
the marginal zones where pannus invades the cortical
bone, whereas juxta-articular bone loss occurs in the
subchondral trabecular bone [9]. Whether these
different localities are related to different molecular
mechanisms remains to be elucidated. However, it
seems clear that a direct synovial-bone contact exists in
the sites where focal bone erosions have been described.
Bone loss processes are mainly due to an increased
number of osteoclasts [10], which is mainly regulated by
the OPG/RANK/RANKL system [13]. Several studies
focused on the expression of RANKL in arthritic tissues
Figure 6 Co-cultures of human peripheral blood mononuclear cells (PBMCs) and chondrocytes. Images of co-cultures of human PBMCs
and chondrocytes after 21 days of differentiation stimulated by macrophage-colony stimulating-factor (M-CSF) in the absence (A) or presence
(B, C) of 10-6M PGE2 (original magnification ×100 and ×200, respectively). Osteoclast differentiation was evaluated by tartrate-resistant acid
phosphatase (TRAP) staining, and osteoclasts were identified by the presence of ≥ 3 nuclei and purple cells.
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have shown that RANKL is increased in the inflamed
synovium of patients with RA [20,38,39]. Furthermore,
synovial RANKL expression was mainly localized in
focal areas of pannus where an invasion of the subchon-
dral bone was observed [40], and this localization coin-
cides with the sites where osteoclast precursors have
been identified [20]. Therefore, RANKL would be able
to differentiate mononuclear cells into osteoclast-activat-
ing bone erosions. These data suggest that the RANKL
produced by synovial cells contributes to RA-associated
bone erosion.
According to our data, subchondral bone loss in AIA
rabbits was not higher in the zones where direct contact
between the bone and the synovial membrane took
place. On the contrary, subchondral bone loss was uni-
form along the AIA subchondral plate, and was similar
at the pannus-bone interface margins and at the weight-
bearing regions. So, it is tempting to speculate that
synovial membrane is not the sole factor responsible for
this specific bone lesion. Within the joint, hyaline chon-
drocytes are also able to synthesize RANKL [28]; how-
ever, scarce attention has been given to its potential role
in RA-related subchondral alterations. According to
these observations, we hypothesize that the RANKL
synthesized in cartilage, a tissue intimately close to the
subchondral bone surface, might have a paracrine effect
modulating subchondral bone remodelling during RA.
Although it has been reported that the synovial mem-
brane may be the major source of RANKL [20], we
observed that, in AIA rabbits, articular cartilage synthe-
sizes about 30% of total RANKL produced in the
arthritic joint. In addition, we found a similar RANKL/
OPG ratio in cartilage and in the synovial membrane,
indicating that both tissues would render an equally
potent resorptive signal. We have demonstrated an
increase in RANKL immunostaining in AIA cartilage as
compared to OA and healthy cartilage, and remarkably
the increase of RANKL/OPG ratio in the cartilage of
AIA rabbits was simultaneous to subchondral bone loss.
Furthermore, rabbits with lesser subchondral bone loss,
such as the OA rabbits in our study, also showed lower
resorptive signal in the cartilage. In contrast, although
RANKL expression increases accordingly with the
degree of synovial inflammation in pannus-associated
regions, the RANKL/OPG ratio remained similar in all
three rabbit groups.
Until now, no data have been published demonstrat-
ing a direct effect on mature chondrocytes of the
RANKL synthesized in cartilage, although scarce
approaches have been made available in the literature.
In this sense, it is also unknown whether a putative
effect of RANKL in chondrocytes would be mediated
by its receptor RANK or whether the levels of RANK
are sufficient to transduce the RANKL signal [16]. On
the contrary, a variety of studies suggest that RANKL
might have a paracrine effect acting on the subchon-
dral bone [41-43]. We observed that the increase in
the RANKL expression in the cartilage of AIA rabbits
was linked to the presence of extracellular RANKL in
the calcified cartilage of these rabbits. Previous results
from our group have also shown that RANKL is loca-
lized in the extracellular matrix of cartilage in human
OA and could reach the subchondral bone though the
calcified cartilage [28]. These results point out that the
RANKL synthesized by chondrocytes might act on sub-
chondral bone cells stimulating juxta-articular bone
loss. Our observation is also in line with previous data
which demonstrate that soluble RANKL produced by
hypertrophic chondrocytes is a biologically active
molecule during bone growth [42,43] that acts in a
paracrine manner on the subchondral bone plate [44].
We have also shown that RANKL synthesized by
PGE2-stimulated mature articular chondrocytes is also
biologically active and is responsible for the mononuc-
lear cell differentiation into osteoclasts in the absence
of exogenous RANKL. Indeed, osteoclast formation
was blocked when PBMCs and chondrocyte co-cul-
tures were treated with RANKL inhibitors. The ability
of human synovial cells to stimulate osteoclastogenesis
has been previously reported, although no data exist
on the ability of human chondrocytes to induce osteo-
clast differentiation.
RA treatment with corticosteroids [45] or methotrex-
ate [46] has been described to regulate bone loss, modu-
lating RANKL expression in synovial tissue. In this
context, our results suggest it would be worthwhile to
study whether these pharmacologic agents or other anti-
inflammatory drugs might also prevent the RA-related
bone loss inhibiting the RANKL expression in cartilage.
Conclusions
In summary, we propose a new pathological mechanism
underlying the juxta-articular bone loss associated with
chronic arthritis. It has been previously described that
the synovial membrane is an important source of
RANKL, which is highly involved in the enhanced osteo-
clastic activity responsible for this form of bone loss [5].
However, according to the new mechanism proposed
here, pathological changes in the expression and locali-
zation of RANKL synthesized by chondrocytes might be
also involved in juxta-articular bone loss. These findings
represent an in vivo confirmation of previous anatomical
[47,48] and ex vivo [44] studies, whose results collec-
tively suggest that the calcified cartilage is permeable
and may transport solutes with a molecular weight
lower than 376 kDa.
Martínez-Calatrava et al. Arthritis Research & Therapy 2012, 14:R149
http://arthritis-research.com/content/14/3/R149
Page 11 of 13
Additional material
Additional file 1: Relationships between articular cartilage
parameters and subchondral bone mineral density (BMD). Figure S1
in Additional file 1: A figure showing Spearman correlation between
cartilage damage and subchondral BMD. Figure S2 in Additional file 1: A
figure showing Spearman correlation between receptor activator nuclear
factor-kappaB ligand (RANKL) protein expression in articular cartilage and
subchondral BMD. Figure S3 in Additional file 1: A figure showing
Spearman correlation between RANKL/osteoprotegerin (OPG) ratio in
articular cartilage and subchondral BMD.
Additional file 2: Figures showing the receptor activator nuclear
factor-kappaB ligand (RANKL) distribution pattern in cartilage.
Figure S1 in Additional file 2: A figure showing extracelullar expression of
RANKL in the rabbits with antigen-induced arthritis (AIA). Figure S2 in
Additional file 2: A figure showing negative control of RANKL expression
in the same area (original magnifications ×400).
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